Mevion Medical Systems, Inc., a Boston, MA-based provider of single-room proton therapy systems for the treatment of cancer, secured $55m in funding.
Backers included existing investors Caxton Heath Life Sciences, ProQuest Investments, Venrock, and CHL Medical Partners. Life Sciences Alternative Funding LLC provided debt financing.
The company intends to use the capital to grow business operations in the U.S. and internationally.
Founded in 2004 and led by Joseph K. Jachinowski, CEO, Mevion Medical Systems provides the MEVION S250 proton therapy system, a single-room proton therapy system, designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost and complexity.
The solution, which is cleared by the United States Food and Drug Administration for clinical use.
The company also has international offices in the United Kingdom and Japan.
FinSMEs
25/06/2013